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Abstract
The identiﬁcation of prognostic biomarkers is a priority for patients suffering from high-grade serous ovarian cancer
(SOC), which accounts for >70% of ovarian cancer (OC) deaths. Meanwhile, borderline ovarian cancer (BOC) is a low
malignancy tumor and usually patients undergo surgery with low probabilities of recurrence. However, SOC remains
the most lethal neoplasm due to the lack of biomarkers for early diagnosis and prognosis. In this regard, BORIS (CTCFL),
a CTCF paralog, is a promising cancer biomarker that is overexpressed and controls transcription in several cancer
types, mainly in OC. Studies suggest that BORIS has an important function in OC by altering gene expression, but the
effect and extent to which BORIS inﬂuences transcription in OC from a genome-wide perspective is unclear. Here, we
sought to identify BORIS target genes in an OC cell line (OVCAR3) with potential biomarker use in OC tumor samples.
To achieve this, we performed in vitro knockout and knockdown experiments of BORIS in OVCAR3 cell line followed by
expression microarrays and bioinformatics network enrichment analysis to identify relevant BORIS target genes. In
addition, ex vivo expression data analysis of 373 ovarian cancer patients were evaluated to identify the expression
patterns of BORIS target genes. In vitro, we uncovered 130 differentially expressed genes and obtained the BORIS-
associated regulatory network, in which the androgen receptor (AR) acts as a major transcription factor. Also, FN1,
FAM129A, and CD97 genes, which are related to chemoresistance and metastases in OC, were identiﬁed. In SOC
patients, we observed that malignancy is associated with high levels of BORIS expression while BOC patients show
lower levels. Our study suggests that BORIS acts as a main regulator, and has the potential to be used as a prognostic
biomarker and to yield novel drug targets among the genes BORIS controls in SOC patients.
Introduction
The most frequent epithelial ovarian cancer (OC) type
is serous ovarian cancer (SOC), which accounts for about
90% of the OC cases. On the other hand, borderline
ovarian cancer (BOC), which shows a more favorable
outcome, accounts for an estimated 15–20% of all ovarian
neoplasms. However, SOC is the most lethal gynecologi-
cal neoplasm due to the lack of early diagnosis, prognosis,
treatment, and response biomarkers1. Approximately,
70% of the cases are diagnosed in late stages, where the
disease has already disseminated and the survival rate is
low1–3. Thus, the search for new cancer biomarkers is one
of the main goals in OC research.
In this regard, one protein that has gained interest by its
potential use as a biomarker is the Brother Of the Reg-
ulator of Imprinted Sites (BORIS)4–7. BORIS is a tran-
scriptional factor coded by the CTCFL gene, a paralog of
CTCF. BORIS shows a very speciﬁc expression pattern;
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for example, it is highly expressed in testicular germ cells,
and has very low levels in other somatic tissues8,9.
Remarkably, BORIS expression is reactivated in several
neoplasms, such as lung, breast, prostate, and OC;5,10–12
where it participates in different cellular processes, such
as cell proliferation and apoptosis13,14. Given the above,
BORIS was proposed by the NCI as one of the most
promising cancer antigens15.
Furthermore, BORIS shows high expression levels in
OC patients and is strongly associated with poor prog-
nosis, which suggests that BORIS, or the molecular
network it controls, have a role in OC progression16,17.
To address this question, great efforts have been made
to understand the regulatory function of BORIS in gene
expression; for example, in OC cells, BORIS can act as a
transcriptional activator of the hTERT gene, known for
its important contribution in cell immortalization18.
However, the function of BORIS in OC is still not
completely understood. There are no genome-wide
unbiased studies of BORIS activity to understand the
effect and the extent to which this protein inﬂuences
transcription and oncogenic processes in OC. Thus, the
identiﬁcation and understanding of the regulatory
function of BORIS could help to predict novel drug
targets or to use it as a prognostic biomarker in OC
patients.
Fig. 1 Characterization of BORIS expression in OC-derived cell lines. a Schematic workﬂow of the experimental and bioinformatics approaches
employed. b Relative expression of BORIS mRNA transcripts and BORIS sf1 subfamily of splicing variants. c Relative abundance of BORIS protein
(~70 kDa) using HeLa cell line as a positive control (n= 3). d Western blot densitometry of BORIS KD efﬁciency after siRNA transfection versus
negative Ctrl siRNA. Lower boxes show BORIS and GAPDH representative western blot bands. Three biological replicates were performed.
e Densitometry of BORIS KO efﬁciency after CRISPR/Cas9 plasmid transient transfection versus non-targeting Ctrl CRISPR/Cas9. Lower panel shows
BORIS and GAPDH representative western blot bands. Three biological replicates were performed. KD knockdown, KO knockout, Ctrl control
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Hence, in this study we aimed to investigate the reg-
ulatory role of BORIS in OC from a genome-wide per-
spective using gene expression microarrays and
bioinformatics analyses in OC cell lines and patients’
samples. In vitro, we identiﬁed that BORIS negatively
regulates the androgen receptor (AR) gene, as well as
ﬁbronectin 1 (FN1), family with sequence similarity 129-
member A (FAM129A) and CD97 antigen (CD97) genes,
which are commonly deregulated in OC patients and
associated with poor prognosis. In addition, we evaluated
Fig. 2 Differential expression microarray analysis of OVCAR3 controls, OVCAR3 BORIS KD, and OVCAR3 BORIS KO. a Volcano plots depicting
differentially expressed genes in BORIS KD vs control cells and BORIS KO vs control cells. Selected differentially expressed genes are shown in colored
circles (|fold change| ≥ 1.9 and FDR-adjusted p-value < 0.1). b The number of differentially expressed genes (overexpressed and underexpressed)
identiﬁed in BORIS KD and BORIS KO cells. c Pie chart depicting the percentage of overexpressed and underexpressed genes in BORIS KD and KO
cells. d Heatmap showing the top 20 genes that changed expression (Z-score) upon BORIS depletion (KD and KO). e Venn diagram showing the
number of differentially expressed genes found in BORIS KD-only (yellow), BORIS KO-only (blue), and both BORIS KD and KO cells (green). KD
knockdown, KO knockout
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the expression patterns of CTCFL (BORIS) and their
related targets genes on publicly available OC patient data
sets, which were subsequently validated in an independent
set of samples obtained from SOC, BOC patients, and non
neoplastic fresh tissue.
Results
Characterization of BORIS expression in OC cell lines and
BORIS-deﬁcient cells
Given that CTCFL (BORIS) has been found to be mainly
deregulated in OC samples compared with other types of
neoplasms (Supplementary Fig. S1), the aim of our study was
to explore the participation of BORIS in gene regulation in
OC. This work was addressed by two different experimental
approaches: in vitro using OC cell lines, molecular biology
techniques, and bioinformatics tools; and an ex vivo
approach to evaluate the clinical relevance of BORIS in
samples from OC patients, publicly available in GEO data-
base and in fresh tissue samples from OC (Fig. 1a).
As a ﬁrst approach, we evaluated the transcript and pro-
tein levels of BORIS in a set of three OC-derived cell lines
(OVCAR3, SKOV3, and SW626), to select the most suitable
cell model to carry out the following experiments (Fig. 1b).
The expression of BORIS had been previously reported in
HeLa, therefore we used this cell line as a positive control19.
We evaluated all BORIS transcripts reported using oli-
gonucleotides located in a region shared by all its splicing
variants. Also, a second pair of primers was used to
amplify only the BORIS subfamily 1 of splicing variants
(sf1), because it encodes for the canonic protein20. We
observed that OVCAR3 and SKOV3 cell lines have higher
levels of BORIS expression compared with HeLa. In
addition, the expression levels of sf1 is higher in OVCAR3
cells than in HeLa and the other OC-derived cells
(Fig. 1b). In addition, we evaluated by western blot the
abundance of BORIS in the different cell lines compared
to HeLa (Fig. 1c). We did not observe a signiﬁcant dif-
ference in BORIS among cell lines.
Considering that we were interested in evaluating the
effect of the absence of BORIS expression and its asso-
ciation with OC, we chose OVCAR3 for subsequent
experiments.
To evaluate the expression proﬁles related to BORIS, we
obtained two cellular models with decreased levels: one by
siRNAs transfection (KD), and the second with the
CRISPR/Cas9 system (KO). Then, we compared the endo-
genous protein levels (controls) with the KD and KO cells.
The efﬁciencies of the decrease in KD cells were 40–90%
(Fig. 1d), while the KO cells exhibit 50% decrease (Fig. 1e).
Expression proﬁle analysis in the KD and KO cells
The ﬁrst goal of this work was to identify novel genes
regulated by BORIS in OC; thus, the expression proﬁles of
the KD and KO cells versus controls were obtained with
expression microarrays. Differentially expressed genes
(DEG) in KD/controls and KO/controls were selected
with FDR p-value < 0.1 and |fold change| > 1.9 (Fig. 2a).
We observed that the number of DEG for the KD cells
was 299 (192 overexpressed and 107 underexpressed;
Supplementary Table 1) and 418 (262 overexpressed and
156 underexpressed; Supplementary Table 2) in the KO
cells. GO-term enrichment analysis results was performed
for both conditions (Supplementary Figs. S2, S3). In
addition, we detected that 130 genes were consistent in
both cellular models, where 87 genes were overexpressed
and 43 genes underexpressed (Fig. 2b). In general, we
identiﬁed that the decrease of BORIS in both cellular
models (KD and KO) corresponds to an overexpression of
63% and a decrease of 36% of DEG, suggesting that BORIS
may act mainly as a transcriptional repressor (Fig. 2c).
Surprisingly, we observed that a group of noncoding
genes (SNORDs) showed major expression changes after
KD and KO (Fig. 2d).
With the DEG from the KD and KO cells, we select only
the genes found in both experimental strategies. This was
done to exclude those genes that could be a result of the
experimental technique, and not because of BORIS decrease.
We identiﬁed 130 DEG in both cellular models and the
following studies were based on these genes (Fig. 2b, e).
Identiﬁcation of BORIS-associated network in the KD and
KO cells
To identify a BORIS-associated regulatory network that
provides us of potential novel BORIS targets in OC, we
used the 130 DEG found in the KD and KO cells, and
performed a de novo pathway enrichment analysis with
KeyPathwayMiner (KPM)21. Given a biological network
and set of expression studies, KPM extracts subnetworks
enriched with differentially expressed genes (DEG). This
method allowed us to discover previously uncharacterized
regulatory networks by extracting a BORIS-associated
network from HTRIdb22, a large experimentally validated
human gene regulatory interaction database.
Our results show that the AR gene changes its expres-
sion upon BORIS depletion and is the main transcription
factor that regulates the network (Fig. 3a). In addition,
genes previously related to OC, such as FN1, FAM129A,
and CD97, were identiﬁed as AR targets. Nevertheless, it
was unclear whether BORIS regulates AR directly or
indirectly. Thus, we performed a chromatin immuno-
precipitation assay (ChIP) with an anti-BORIS antibody in
the AR promoter. We observed that BORIS is located at
the AR gene promoter (Fig. 3b).
Finally, to validate the BORIS-associated network, we
proceeded to evaluate the expression changes by qRT-
PCR in the KD and KO cells. Our results show that,
indeed, AR, FN1, FAM129A, and CD97 genes change their
expression levels after BORIS decrease (Figs. 4a, b). In
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accordance with our ﬁndings, expression data from The
Cancer Cell Line Encyclopedia show that ~82% of the
OC-derived cell lines reproduce the same phenomenon
for FN1, FAM129A, and CD97 genes (Supplementary
Fig. S4). The latter proposes that BORIS acts as a tran-
scriptional repressor of AR, FN1, FAM129A, and CD97
genes, not only in OVCAR3 but also in a larger set of OC-
derived cell lines, suggesting that this phenomenon might
be related to OC biology.
Expression analysis of CTCFL (BORIS), AR, FN1, and
FAM129A and CD97 genes in SOC, BOC, and non neoplastic
samples
Previously, we identiﬁed that high levels of AR, FN1,
FAM129A, and CD97 transcripts are associated to a
decrease in BORIS expression in OC cell lines. Thus, to
determine if this expression pattern is similar in OC
samples, we analyzed 343 expression microarrays from
the GEO database (43 non neoplastic, 288 SOC, and 12
BOC samples).
We extracted the expression values of BORIS, AR, FN1,
FAM129A, and CD97 genes and plotted heatmaps for non
neoplastic, SOC, and BOC samples (Fig. 5a). Our data
reveals a wide heterogeneity among normal and cancer
samples. First, we observed two main dendrogram bran-
ches in SOC samples: BORIS positive (red) and BORIS
negative (green); in contrast to non neoplastic and BOC
samples, which show low levels of BORIS. An important
subset of SOC patients exhibits high levels of BORIS
(42–47%; Fig. 5a). Furthermore, in this group of patients,
we can also ﬁnd different expression combinations with
AR, FN1, FAM129A, and CD91; however, an important
group of samples with high levels of BORIS also show low
levels of AR (28% of samples) along with low levels of FN1
(13%; Fig. 5b), in agreement with our in vitro ﬁndings,
suggesting that both genes might be playing an important
role in SOC.
Furthermore, due to de incidence of SOC patients, we
aimed to classify this type of OC into clusters based on the
expression patterns of these genes (Fig. 5a, c). We iden-
tiﬁed a clear expression pattern in clusters number 2 and
6, which correspond to the phenomenon previously
characterized in vitro in OVCAR3 cell line (Fig. 3), where
the presence of BORIS is associated with low levels of AR,
FN1, FAM129A, and CD97 (Cluster 2), while the absence
of BORIS has the opposite behavior (Cluster 6; Supple-
mentary Figs. S5, S6).
In addition, we evaluated BORIS, AR, FN1, CD97, and
FAM129A in tissue from patients’ samples to assess their
clinical value. For instance, we wondered if the expression
of these genes could be associated with a clinical feature.
Thus, we obtained the relative expression levels of these
genes in 11 SOC, 10 BOC, and 8 non neoplastic patients
of a second cohort. We tested the results against clinical
variables, and we identiﬁed that BORIS and AR genes are
not associated with CA-125 expression, tumor size or
FIGO stage (Table 1). However, we found that BORIS was
associated with malignancy; for instance, SOC patients
show signiﬁcant higher levels of BORIS compared with
BOC and non neoplastic samples (p= 0.017), in agree-
ment with the previous ﬁnding in the large cohort from
GEO database (Table 1). The later proposes BORIS as a
relevant deregulated gene in OC, particularly in SOC,
where a subset of patients show an inverse association
between BORIS and AR expression, and is associated with
tumor malignancy.
In summary, our results show that BORIS binds to AR
gene promoter and acts as a transcriptional repressor of
AR. In addition, the decrease of BORIS levels is associated
Fig. 3 Identiﬁcation and validation of AR as a target gene in the
BORIS-associated transcriptional regulatory network. a BORIS-
associated transcriptional regulatory network identiﬁed with KPM
using differentially expressed genes found in BORIS KD and KO cells
(139 genes). Gray circles indicate target genes, white circle shows the
main transcription factor and arrows point the direction of
transcriptional regulation. b qPCR evaluation of the products obtained
from the chromatin immunoprecipitation assay of the AR promoter
and positive control (NY-ESO-1 promoter) precipitated with anti-BORIS
antibody in OVCAR3 cells. As a positive control antibody, we used anti-
CTCF, and as a negative control we used the IgG antibody
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with an increase in FN1, FAM129A, and CD97 gene
expression (Fig. 6a). Furthermore, in OC patients, BORIS
is overexpressed in 47% of SOC samples, and is down-
regulated in borderline and non neoplastic samples, thus
it is signiﬁcantly associated with malignancy. Our data
also indicate that a fraction of SOC samples with over-
expression of BORIS (47%) can show either under-
expression (28%) or overexpression (19%) of AR,
indicating that in OC samples, the relationship between
BORIS and AR found in OVCAR3 cell line might not
necessarily happen in all OC samples (Fig. 6b). Never-
theless, we still ignore whether the different combinations
of BORIS and AR expression levels are associated with a
speciﬁc outcome, and if their joint use as prognostic
biomarkers is beneﬁcial for SOC patients. In this regard,
further studies are needed to address if BORIS and AR
can be used together as prognostic biomarkers in OC.
Discussion
SOC is as one of the most lethal gynecologic malig-
nancies worldwide, and we lack effective biomarkers to
improve the outcome23. Currently, only CA-125 and HE4
antigens are used in the medical practice, but they lack
sensitivity24. Thus, the identiﬁcation of novel tumor bio-
markers that could beneﬁt patients’ outcome is a priority
in OC research. One of the proteins that has gained
interest, given its potential use as a cancer biomarker, is
BORIS5,6. This protein was proposed as a priority bio-
marker by the National Cancer Institute, because its
deregulation is related to oncogenic properties, and as a
Fig. 4 Validation of BORIS-associated transcriptional regulatory network. a RT-qPCR assays of AR, FN1, CD97, and FAM129A in KD and Ctrl cells. b
RT-qPCR assays of AR, FN1, CD97, and FAM129A in KO and Ctrl cells. KD knockdown, KO knockout, Ctrl control
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biomarker could be used for its speciﬁcity and immuno-
genicity15. Previously, some studies have shown that the
decrease of BORIS is associated with decreasing cell
proliferation and cell viability6,25. Hence, we aimed to
identify genes regulated by BORIS, which could provide
some insights in the biology of OC. An analysis of dif-
ferential expression exhibits that several small nuclear and
small nucleolar RNAs are the most affected genes in the
absence of BORIS. To understand the function of BORIS
from a systems perspective, we applied KPM to integrate
our expression studies with known gene regulatory
interactions to extract novel disease pathways and
potential drug targets26. Enriched with the 130 DEG, we
identiﬁed and experimentally validated the AR gene as
one of the main regulators of the BORIS-associated reg-
ulatory network. This type of analysis may suggest that
BORIS could have its effect on transcriptional regulation
by altering the levels of AR through its binding to the AR
promoter. Our data show biological and therapeutic
relevance, since AR has been used as a biomarker of dif-
ferent neoplasms, such as prostate cancer, and is an
important druggable target27. Because the ovary is also
Fig. 5 Expression proﬁles of BORIS, AR, FN1, FAM129A, and CD97 genes in OC samples selected from the GEO database. a Hierarchical
clustering of 343 samples (43 non neoplastic, 288 SOC, and 12 BOC samples) by BORIS, AR, FN1, FAM129A, and CD97 expression levels (row Z-score).
Columns show patient samples, and rows show genes. SOC samples are classiﬁed in seven clusters, shown in lower panel. b Percentage of the SOC
samples with low or high BORIS, AR, FN1, and FAM129A expression. Percentage of samples with low BORIS and high AR, FN1, and FAM129A expression
are highlighted in color, as well as the samples with high BORIS and low AR, FN1, and FAM129A expression. c Table of SOC sample frequencies
classiﬁed on each cluster. OC ovarian cancer, H high, L low, SOC serous ovarian cancer, BOC borderline ovarian cancer
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responsible for the synthesis of AR, it would be of great
importance the search for biomarkers related to this
protein28–30. Interestingly, our results from KPM
demonstrated that BORIS is partly responsible for the
regulation of AR gene expression, and in turn, AR estab-
lishes a gene regulatory network with genes such as FN1,
CD97, and FAM129A, which are related with poor prog-
nosis, chemoresistance, and metastasis in several cancers,
Table 1 Clinical and demographic characteristics of patients
Expression
N= 29 BORIS AR FN1 FAM129A CD97
SOC 11 37.9% p= 0.017 p= 1.000 p= 0.895 p= 0.195 p= 0.180
BOC 10 34.4%
Non neoplastic 8 27.5%
Age X= 48.9 (21–81) p= 0.793 p= 0.474 p= 0.013 p= 0.013 p= 0.483
< 45 years 9 (31%)
> 45 years 20 (69%)
Patient follow-up 38.3 months (1–80)
Premenopause 12 (41%) p= 0.428 p= 0.774 p= 0.876 p= 0.876 p= 0.432
Postmenopause 17 (59%)
Number of births 2.3 (0–11) p= 0.913 p= 0.507 p= 0.017 p= 0.017 p= 0.311
BMI X= 26.7 p= 0.888 p= 0.663 p= 0.018 p= 0.018 p= 0.947
SOC 27.3
BOC 26.5
Non neoplastic 26.2
CA-125 Pre-Qx X= 3649.1 p= 0.467 p= 0.488 p= 0.483 p= 0.586 p= 1.000
SOC 478.2
BOC 9968.2
Non neoplastic 110.3
Tumor size X= 16.2 p= 0.208 p= 0.628 p= 0.812 p= 0.558 p= 0.466
> 10 CM SOC 11 (100%)
> 10 CM BOC 7 (70%)
Ascites Yes 6 (28%) p= 0.172 p= 0.565 p= 0.291 p= 0.457 p= 0.375
No 15 (72%)
Peritoneal implants SOC 6 (54%) p= 0.432 p= 0.183 p= 0.129 p= 0.382 p= 0.192
BOC 2 (20%)
FIGO SOC BOC
I 0 5 (50%) p= 0.510 p= 1.000 p= 0.523 p= 0.171 p= 0.142
II 3 (27%) 1 (10%)
III 8 (73%) 4 (40%)
IV 0 0
Optimal cytoreduction SOC 6 (54%) p= 0.329 p= 0.236 p= 0.186 p= 0.112 p= 0.498
BOC 100%
Mortality SOC 27% p= 0.060 p= 0.420 p= 0.527 p= 0.636 p= 0.220
BOC 0%
Non neoplastic 0%
p < 0.05 is statistically signiﬁcant
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including OC31–33. Previous studies are limited to the
identiﬁcation of possible target genes by evaluating
changes in gene expression by increasing or decreasing
BORIS levels;5,6,11,19,34 however, our de novo pathway
enrichment analysis allowed us to perform a novel
selection (based on hundreds of experimental data avail-
able in public databases) of potential genes relevant in
cancer, which are closely related through AR and BORIS.
In conclusion, we found that in both, BORIS KD and KO
models, BORIS regulates several genes, functioning
mainly as a transcriptional repressor. Remarkably, BORIS
acts as a transcriptional repressor of AR gene and binds to
its promoter. The latter is of great relevance given the
importance of AR deregulation in the development and
malignancy of many types of cancer, also due to the
current use of AR gene as a prognostic biomarker and
therapy target in cancer, such as prostate cancer. In
addition, our ﬁndings show that BORIS can also regulate
other genes involved in OC, such as FN1, FAM129A, and
CD97. Finally, we found a subset of SOC patients that
show BORIS overexpression, which is signiﬁcantly asso-
ciated with malignancy.
Collectively, our in vitro and ex vivo studies conﬁrm
that BORIS has the potential to be used as a prognostic
biomarker in SOC and to yield novel druggable targets
among the regulatory network that BORIS controls.
Materials and methods
Cell lines culture
The cancer cell lines OVCAR3, SKOV3, SW626, and
HeLa were obtained from ATCC (Manassas, VA, USA),
and subcultured as described by the supplier.
Fig. 6 Schematic model of AR transcriptional repression mediated by BORIS and its clinical relevance in ovarian cancer patients. a BORIS is
recruited to the AR gene promoter and mediates its transcriptional repression in OVCAR3 cell line. The AR levels reduction and the endogenous
presence of BORIS have an effect in the FN1, CD97, and FAM129A gene repression. In contrast, in BORIS KO and KD cells, the absence of BORIS allows
the AR gene activation, which could increase the transcript levels of FN1, CD97, and FAM129A. b A subset of SOC patients show high levels of BORIS,
which is associated with malignancy in contrast to BOC and non neoplastic patients which have low levels of BORIS. OC ovarian cancer, BOC
borderline ovarian cancer, SOC serous ovarian cancer, KO knockout, KD knockdown
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Knockdown and Knockout assays
To knockdown (KD) expression of BORIS, OVCAR3
cells were transfected with a pool of small interfering
RNAs (siRNAs) (Cat. A-003819-100-0005, Dharmacon,
Lafayette, CO, USA) or non-targeting control siRNA (Cat.
D-001910-10-10, Dharmacon) and were incubated for
48 h in Accell Delivery Media (Cat. B-005000, Dharma-
con). The assays were performed by triplicate.
Knockout (KO) of BORIS expression was performed by
transfection of OVCAR3 cells with 2 μg of BORIS (Cat.
sc-403313, SCBT, Dallas, TX, USA) or control CRISPR/
Cas9 (Cat. Sc-418922, SCBT) plasmids. The assays were
performed by triplicate. Following experiments were
performed 24 h post transfection.
Western blot assays
Western blot assays were performed with 30 μg of total
protein. Primary and secondary antibodies used are
described in Supplementary Table 3. Canonic BORIS
abundance was determined by standard densitometry
analysis, using ImageJ software (NIH, USA) with GAPDH
as normalizing protein.
RNA extraction, cDNA, and qRT-PCR analysis
The total RNA was extracted with TRIzol Reagent (Cat.
15596026, Invitrogen, Carlsbad, CA, United States), and
the integrity and quality were analyzed with TapeStation
2200. cDNA was obtained with the GeneAmp PCR Core
Kit (Cat. N8080143, Thermo Scientiﬁc, Waltham, MA,
USA) using oligo(dT). qRT-PCR assays were performed
on StepOnePlus using SYBR Green Master Mix (Cat.
4309155, Applied Biosystems, Foster City, CA, USA). All
data were normalized to GAPDH using the ΔΔCt method.
Primers used are described in Supplementary Table 4.
Experiments were performed by triplicate.
Microarray analysis: hybridization and analysis
The GeneChip Human Gene 2.0 ST oligonucleotide
arrays (Affymetrix, Santa Clara, CA, USA) were hybri-
dized with two control samples of OVCAR3, three sam-
ples of OVCAR3 KD, and three samples of OVCAR3 KO
cells, according to the instructions provided by the
manufacturer.
Data normalization was performed with robust multi-
array analysis (RMA). DEG were selected with “Limma”
package35 and those with |fold change| > 1.9 and FDR-
adjusted p-value < 0.1 were selected for further down-
stream analysis. De novo pathway enrichment analysis was
performed with KPM21 with the Greedy search algorithm
and the INES search strategy. We used as input of KPM, a
regulatory network constructed from 51871 interactions
found in the human transcriptional regulation interaction
database (HTRIdb)22. Microarrays data have been
deposited at the National Center for Biotechnology
Information Gene Expression Omnibus (NCBI GEO
Series Accession # GSE130163).
Chromatin immunoprecipitation assays (ChIP)
OVCAR3 cells were cultured at 80% of conﬂuence,
chromatin was extracted according to the OneDay ChIP
Kit (Cat. kch-oneDIP- 180, Diagenode, Denville, NJ,
USA). Two independent chromatin preparations were
analyzed. As a negative control, we used an IgG antibody
provided by the kit. The antibodies and primers used are
listed in Supplementary Tables 3 and 4.
Patients samples
The ovarian tumor samples were collected from
patients undergoing surgical resections at the INCan
(Mexico City, Mexico) with previous written consent
and the approval of the ethical committee (approval
number 015/037/ICI). We analyzed a total of 21 sam-
ples from patients diagnosed with OC (11 SOC, 10
BOC), and eight non neoplastic ovarian samples
obtained from January 1st, 2014 to December 31st,
2016. Demographics, prognostic markers, and epide-
miologic exposure variables were obtained from the
medical record.
RNA extraction from patient samples
The tissue from patients was stored in RNAlater RNA
Stabilization Reagent (Cat. AM7020, Invitrogen) at −20 °
C. RNA from samples was obtained according to Peña-
Llopis et al.36.
GEO expression microarray analysis
Gene expression data from OC patients, evaluated by
GeneChip Human Genome U133A 2.0 Plus arrays, were
obtained from the GEO (Accession IDs: GSE14001,
GSE18520, GSE19352, GSE36668, GSE38666, GSE63885,
GSE40595 and GSE26193)37–45. A total of 343 samples
were analyzed (43 from non neoplastic samples, 288 were
from SOC samples, and 12 BOC patients). Batch effects
were corrected with ComBat function from the “sva”
package46. Then, normalized expression values were
obtained for BORIS, AR, FN1, FAM129A, and CD97
genes. Heatmaps were generated using the “Complex-
Heatmap” package47, clustering was performed with
hierarchical clustering where the optimal number of
clusters was selected using the “NbClust” package48.
Statistical analysis
The data from cell lines are shown as the mean ±
standard error. The differences between groups were
analyzed with a paired Student’s t test comparing the
samples with the controls. Differences between groups
were considered statistically signiﬁcant when p < 0.05,
p < 0.01, p < 0.001, and p < 0.0001.
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For patient samples, we performed Chi-square test and
Fisher’s exact test using STATA software version
13.0 software (StataCorp, TX, USA), to assess the rela-
tionship between BORIS, AR, FN1, FAM129A, and CD97
with clinicopathological characteristics. P < 0.05 was
considered statistically signiﬁcant.
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